Perspectives and mechanisms for targeting mitotic catastrophe in cancer treatment

Z Bai, Y Zhou, Y Peng, X Ye, L Ma - … et Biophysica Acta (BBA)-Reviews on …, 2023 - Elsevier
Mitotic catastrophe is distinct from other cell death modes due to unique nuclear alterations
characterized as multi and/or micronucleation. Mitotic catastrophe is a common and virtually …

RhoJ: an emerging biomarker and target in cancer research and treatment

J Shen, X Su, S Wang, Z Wang, C Zhong… - Cancer Gene …, 2024 - nature.com
Abstract RhoJ is a Rho GTPase that belongs to the Cdc42 subfamily and has a molecular
weight of approximately 21 kDa. It can activate the p21-activated kinase family either directly …

In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker Genes

S Alamery, A AlAjmi, TA Wani, S Zargar - Medicina, 2023 - mdpi.com
Background and objectives: Non-small cell lung cancer (NSCLC) is often caused by EGFR
mutations, leading to overactive cell growth pathways. Drug resistance is a significant …

Network based approach to identify interactions between Type 2 diabetes and cancer comorbidities

SI Nayan, MH Rahman, MM Hasan, SMRH Raj… - Life Sciences, 2023 - Elsevier
High blood sugar and insulin insensitivity causes the lifelong chronic metabolic disease
called Type 2 diabetes (T2D) which has a higher chance of developing different …

Impact of tissue-agnostic approvals on management of primary brain tumors

MS Ahluwalia, AA Khosla, A Ozair, MA Gouda… - Trends in cancer, 2024 - cell.com
Novel tissue-agnostic therapeutics targeting driver mutations in tumor cells have been
recently approved by FDA, driven by basket trials that have demonstrated their efficacy and …

[HTML][HTML] Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery

D Kamath, T Iwakuma, SH Bossmann - … : Nanotechnology, Biology and …, 2024 - Elsevier
Among the tumor suppressor genes, TP53 is the most frequently mutated in human cancers,
and most mutations are missense mutations causing production of mutant p53 (mutp53) …

The anti-non-small cell lung cancer effect of Diosbulbin B: Targeting YY1 induced cell cycle arrest and apoptosis

JQ Zhao, QQ Zhou, Y Sun, T Yu, Y Jiang, HJ Li - Phytomedicine, 2024 - Elsevier
Background Toxic components frequently exhibit unique characteristics and activities,
offering ample opportunities for the advancement of anti-cancer medications. As the main …

Hawthorn with “homology of medicine and food”: a review of anticancer effects and mechanisms

Z Zhou, Y Nan, X Li, P Ma, Y Du, G Chen… - Frontiers in …, 2024 - frontiersin.org
Over the past few years, there has been a gradual increase in the incidence of cancer,
affecting individuals at younger ages. With its refractory nature and substantial fatality rate …

Cell cycle-specific phosphorylation of p53 protein in A549 cells exposed to cisplatin and standardized air pollutants

A Niechoda, K Milewska, J Roslan, K Ejsmont… - Frontiers in …, 2023 - frontiersin.org
Exposure to particulate matter is associated with DNA damage and the risk of lung cancer.
Protein p53 is activated by multi-site phosphorylation in the early stages of DNA damage …

P53 与肿瘤代谢的最新研究进展

翟海晖, 刘元祺, 张从政, 官立萍, 韩涛 - 中国癌症杂志, 2023 - china-oncology.com
由TP53 编码的P53 蛋白是防止细胞癌变所需的关键因子, 有广泛而强大的功能. P53
在诱导细胞周期停滞, DNA 损伤修复, 细胞凋亡和衰老等过程中发挥重要作用 …